Advances and Breakthroughs in Stem Cell Research

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: 25 February 2025 | Viewed by 3562

Special Issue Editors


E-Mail Website
Guest Editor
Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA
Interests: investigating the mechanisms underlying the constitutive induced heteromerization of opioid receptors
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Cellinfinitybio, San Francisco, CA, USA
Interests: induced pluripotent stem cell-derived NK and T cells; hematopoietic stem cells; cancer immunotherapy; therapeutic antibody; host-pathogen interaction; immune dysfunction; off the shelf therapy; checkpoint inhibitors; metalloproteases; small molecule inhibitors; cardiovascular disorders; tuberculosis; sarcoidosis; allergy and asthma

Special Issue Information

Dear Colleagues,

This Special Issue will center around the latest cutting-edge breakthroughs in stem cell research within immunotherapy and regenerative medicine. In recent years, advancements in stem cell research have opened promising avenues for treating and potentially curing diverse conditions such as cancers, metabolic disorders, and neurodegenerative diseases. The immense potential of specific human iPSC-derived cell lineages, including CAR T cells, CAR NK cells, neurons, cardiomyocytes, and pancreatic islets, holds transformative possibilities in revolutionizing medical practices through the development of innovative therapies. This Special Issue will explore a range of topics related to stem cell therapy, encompassing iPSC (induced pluripotent stem cell)- or hematopoietic-stem-cell-derived, therapeutically relevant lineages. We welcome original manuscripts and reviews that delve into these subjects, contributing to a more profound comprehension of recent advancements and challenges in these domains.

Prof. Dr. Alexander E. Kalyuzhny
Dr. Hemant Kumar Mishra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stem cell
  • induced pluripotent stem cell
  • iPSC
  • hematopoietic stem cell

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 4521 KiB  
Article
A Novel Recombinant Vitronectin Variant Supports the Expansion and Differentiation of Pluripotent Stem Cells in Defined Animal-Free Workflows
by Xi Lu, Eli Perr, Tahmina Naqvi, David Galitz, Marnelle Andersen, David Grabowski, Anthony Person, Alex Kalyuzhny and Kevin C. Flynn
Cells 2024, 13(18), 1566; https://doi.org/10.3390/cells13181566 - 17 Sep 2024
Viewed by 806
Abstract
An essential aspect of harnessing the potential of pluripotent stem cells (PSCs) and their derivatives for regenerative medicine is the development of animal-free and chemically defined conditions for ex vivo cultivation. PSCs, including embryonic and induced PSCs (iPSCs), are in the early stages [...] Read more.
An essential aspect of harnessing the potential of pluripotent stem cells (PSCs) and their derivatives for regenerative medicine is the development of animal-free and chemically defined conditions for ex vivo cultivation. PSCs, including embryonic and induced PSCs (iPSCs), are in the early stages of clinical trials for various indications, including degenerative diseases and traumatic injury. A key step in the workflows generating these cells for more widespread clinical use is their safe and robust ex vivo cultivation. This entails optimization of cell culture media and substrates that are safe and consistent while maintaining robust functionality. Here, we describe the design of a human vitronectin (hVTN) variant with improved manufacturability in a bacterial expression system along with improved function in comparison to wild-type VTN and other previously characterized polypeptide fragments. In conjunction with an animal component-free media formulation, our hVTN fragment provides animal-free conditions for the enhanced expansion of iPSCs. This hVTN variant also supports the reprogramming of PBMCs into iPSCs. Furthermore, we show that these iPSCs can be efficiently differentiated into the three major germ layers and cortical neurons, thereby closing the loop on a completely defined animal-free workflow for cell types relevant for regenerative medicine. Full article
(This article belongs to the Special Issue Advances and Breakthroughs in Stem Cell Research)
Show Figures

Figure 1

17 pages, 26759 KiB  
Article
A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs
by Neha R. Dhoke, Hyunkee Kim, Karim Azzag, Sarah B. Crist, James Kiley and Rita C. R. Perlingeiro
Cells 2024, 13(11), 972; https://doi.org/10.3390/cells13110972 - 4 Jun 2024
Cited by 2 | Viewed by 1899
Abstract
Mutations in the DMD gene cause fatal Duchenne Muscular Dystrophy (DMD). An attractive therapeutic approach is autologous cell transplantation utilizing myogenic progenitors derived from induced pluripotent stem cells (iPSCs). Given that a significant number of DMD mutations occur between exons 45 and 55, [...] Read more.
Mutations in the DMD gene cause fatal Duchenne Muscular Dystrophy (DMD). An attractive therapeutic approach is autologous cell transplantation utilizing myogenic progenitors derived from induced pluripotent stem cells (iPSCs). Given that a significant number of DMD mutations occur between exons 45 and 55, we developed a gene knock-in approach to correct any mutations downstream of exon 44. We applied this approach to two DMD patient-specific iPSC lines carrying mutations in exons 45 and 51 and confirmed mini-DYSTROPHIN (mini-DYS) protein expression in corrected myotubes by western blot and immunofluorescence staining. Transplantation of gene-edited DMD iPSC-derived myogenic progenitors into NSG/mdx4Cv mice produced donor-derived myofibers, as shown by the dual expression of human DYSTROPHIN and LAMIN A/C. These findings further provide proof-of-concept for the use of programmable nucleases for the development of autologous iPSC-based therapy for muscular dystrophies. Full article
(This article belongs to the Special Issue Advances and Breakthroughs in Stem Cell Research)
Show Figures

Figure 1

Back to TopTop